Stay updated with breaking news from Including Selective. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Two-year results from both PROTECT and DUPLEX pivotal Phase 3 studies demonstrate treatment with sparsentan has the potential to preserve kidney function and significantly delay time to kidney...
SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present preliminary findings from the SPARTAN Study evaluating
SAN DIEGO, Sept. 26, 2023 -- Travere Therapeutics, Inc. today announced that the Company and its collaborators will present preliminary findings from the SPARTAN Study evaluating the potential...
FILSPARI® achieved a clinically meaningful difference vs. irbesartan in eGFR total slope [p= 0.058] and eGFR chronic slope [p=0.037]. Patients treated with FILSPARI over two years exhibited one of...
FinancialContent fully hosted finance channel